OPTHOptimi Health Corp

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research PR Newswire VANCOUVER, BC, June 16, 2026 Two naturally derived finished drug products, at 1mg and 2mg, give research...

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial PR Newswire VANCOUVER, BC, June 10, 2026 The shipment of naturally derived psilocybin, comprising...

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development PR Newswire VANCOUVER, BC, June 8, 2026 Recent US executive order named ibogaine compounds among the psychedelic therapies...

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, welcomed final recommendations from Australia’s Therapeutic Goods Administration regarding its Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens eligible therapy teams, expands treatment settings beyond […]

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia PR Newswire VANCOUVER, BC, May 29, 2026...

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting PR Newswire VANCOUVER, BC, May 20, 2026 Common Shares to Trade on the Nasdaq Capital Market Under...